Supplemental Figure S1. Flow-chart of patients with available measurements of plasma microvesicle levels at six months of follow-up according to their Child-Pugh stage at baseline and at month six.

Among the 90 included patients, eight died and seven underwent liver transplantation. In the remaining 75 patients, two underwent transjugular intrahepatic portosystemic shunt (TIPS) placement, two experienced a thromboembolic event, and two developed neoplasia, which contraindicated subsequent measurement of plasma MVs according to our protocol. For 13 additional patients, blood samples were not available at 6 months. Solid thin arrows indicate patients with no change in Child-Pugh stage between baseline and 6 months. Solid thick arrows indicate patients who worsened their Child-Pugh stage between baseline and 6 months. Dotted arrows indicate patients who improved their Child-Pugh stage between baseline and 6 months.
90 patients with available MVs levels at day 0

Baseline Child-Pugh stage (whole cohort)

- CP-A N=30
  - Missing blood sample at month 6: 4
    - Thromboembolic event: 1
  - CP-A N=25
    - CP-A N=23
      - Child-Pugh stage at month 6 in patients with available measurement of plasma MVs levels at month 6
      - CP-A N=34
  - CP-B N=20
    - Missing blood sample at month 6: 5
      - Death: 2
      - TIPS: 2
      - Liver transplantation: 1
    - CP-B N=10
      - CP-B N=9
        - CP-B N=6
      - CP-B N=1
  - CP-C N=11
    - Missing blood sample at month 6: 4
      - Death: 6
      - Liver transplant: 6
      - Thromboembolic event: 1
      - Neoplasia: 2
    - CP-C N=4

56 patients with available MVs levels at 6 months